S.2691 - Opioid Crisis Accountability Act of 2018115th Congress (2017-2018)
|Sponsor:||Sen. Sanders, Bernard [I-VT] (Introduced 04/17/2018)|
|Committees:||Senate - Finance|
|Latest Action:||Senate - 04/17/2018 Read twice and referred to the Committee on Finance. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.2691 — 115th Congress (2017-2018)All Information (Except Text)
Introduced in Senate (04/17/2018)
Opioid Crisis Accountability Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks.
The bill penalizes drug manufacturers or distributors who illegally advertise, market or distribute an opioid product, including by (1) imposing a civil fine or salary confiscation, (2) revoking any remaining period of market exclusivity for such product, (3) requiring reimbursement of federal funding received for such product, and (4) prohibiting certain tax credits.